Business Context and Reporting Period
This Form 8-K Current Report was filed by Viking Therapeutics, Inc. on July 28, 2021. The filing details the entry into a new material definitive agreement for an equity offering and the termination of a prior agreement.
Key Financial Metrics and Capital Structure
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization of a new capital raise.
- Proposed Offering Size: Up to $125.0 million in common stock.
- Commission Rate: 3.0% of the gross sales price of shares sold.
- Previous Offering Capacity: $75.0 million (under the terminated 2019 agreement).
Material Changes
The Company executed two significant changes regarding its capital raising mechanisms on July 28, 2021:
- New ATM Agreement: Entered into an At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated; Truist Securities, Inc.; and H.C. Wainwright & Co., LLC. This allows the sale of up to $125.0 million of common stock at market prices.
- Termination of Prior Agreement: Voluntarily terminated the 2019 ATM Agreement with Stifel and Oppenheimer & Co. Inc. No shares were sold under the 2019 agreement prior to its termination.
Outlook, Management Commentary, and Risks
Use of Proceeds: The Company intends to use net proceeds from the new offering for the continued development of its VK2809 and VK0214 programs, general research and development, working capital, and general corporate purposes.
Contingencies: The sale of shares is contingent upon the effectiveness of the Registration Statement on Form S-3 filed on July 28, 2021. The Company has no obligation to sell any shares and may suspend offers at any time.
Risks: The filing notes that the Registration Statement has not yet become effective, and no offers to buy shares may be accepted until that time.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 Registration Statement filed on July 28, 2021.
- Monitor future filings for actual share sales and proceeds generated under the new ATM Agreement.
- Review the full text of the ATM Agreement (Exhibit 10.1) for specific termination rights and indemnification clauses.
- Confirm the current cash position and burn rate to assess the necessity of the $125.0 million raise for the VK2809 and VK0214 programs.